Background Over 50% of patients with head and neck squamous cell
Background Over 50% of patients with head and neck squamous cell carcinoma (HNSCC) present with locoregionally advanced disease. USA or European countries. However, resistance frequently occurs, and fresh approaches, such as for example focusing on multiple ErbB family, may be needed. Afatinib, an irreversible ErbB family members blocker, exhibited antiproliferative activity in preclinical versions and … [Read more…]